TLR3-Induced Placental miR-210 Down-Regulates the STAT6/Interleukin-4 Pathway by Kopriva, Shelley E. et al.
TLR3-Induced Placental miR-210 Down-Regulates the
STAT6/Interleukin-4 Pathway
Shelley E. Kopriva, Valorie L. Chiasson, Brett M. Mitchell, Piyali Chatterjee*
Department of Internal Medicine, Division of Nephrology and Hypertension, Scott & White Healthcare/Texas A&M Health Science Center, Temple, Texas, United States of
America
Abstract
Several clinical studies have reported increased placental miR-210 expression in women with PE compared to normotensive
women, but whether miR-210 plays a role in the etiology of PE is unknown. We reported that activation of TLR3 produces
the PE-like symptoms of hypertension, endothelial dysfunction, and proteinuria in mice only when pregnant, but whether
TLR3 activation in pregnant mice and human cytotrophoblasts (CTBs) increases miR-210 and modulates its targets related to
inflammation are unknown. Placental miR-210 levels were increased significantly in pregnant mice treated with the TLR3
agonist poly I:C (P-PIC). Both HIF-1a and NF-kBp50, known to bind the miR-210 promoter and induce its expression, were
also increased significantly in placentas of P-PIC mice. Target identification algorithms and gene ontology predicted STAT6
as an inflammation-related target of miR-210 and STAT6 was decreased significantly in placentas of P-PIC mice. IL-4, which is
regulated by STAT6 and increases during normotensive pregnancy, failed to increase in serum of P-PIC mice. P-PIC TLR3 KO
mice did not develop hypertension and placental HIF-1a, NF-kBp50, miR-210, STAT6, and IL-4 levels were unchanged. To
determine the placental etiology, treatment of human CTBs with poly I:C significantly increased HIF-1a, NF-kBp50, and miR-
210 levels and decreased STAT6 and IL-4 levels. Overexpression of miR-210 in CTBs decreased STAT6 and IL-4 while
inhibition of miR-210 increased STAT6 and IL-4. These findings demonstrate that TLR3 activation induces placental miR-210
via HIF-1a and NF-kBp50 leading to decreased STAT6 and IL-4 levels and this may contribute to the development of PE.
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Introduction
Preeclampsia (PE) is a vascular disorder that affects 5–8% of all
pregnancies and is diagnosed by the onset of hypertension and
proteinuria at or after the 20th week of gestation [1]. PE is one of
the leading causes of preterm birth as 10% of babies are born
before 34 weeks of gestation. Although the pathophysiology of PE
is still unknown, a major contributing factor is excessive activation
of the maternal immune system and inflammation [2,3]. One
possible cause of the inflammatory state may be excessive
activation of Toll-like receptors (TLRs) which are present
throughout utero-placental tissues to guard against foreign
pathogens [4–7]. TLRs recognize exogenous pathogens and
endogenous ligands from necrotic tissues and initiate innate
immune responses by inducing pro-inflammatory cytokines and
type I interferons (IFNa/b) [8,9]. Out of the many TLRs, double-
stranded RNA viruses bind to TLR3 leading to activation of the
adaptor molecule TRIF, which is involved in IRF3 and NF-kB
activation, and subsequently leads to IFN-b production and the
expression of IFN-inducible genes [10]. Several studies link viral
infections with a 2-fold increased risk of developing PE [11,12].
We have reported previously that TLR3 activation is increased in
placentas of women with PE and that activating the maternal
immune system with the TLR3 agonist poly I:C in pregnant mice
leads to PE-like symptoms [13,14]. TLR3-induced PE mice
exhibit increased serum levels of pro-inflammatory cytokines
including IFNc, TNFa, and IL-12, while levels of the anti-
inflammatory cytokine IL-4 fail to increase [13]. Clinical studies
also reported increased levels of pro-inflammatory cytokines in
women with PE and decreased levels of IL-4 [15,16]. Thus, we
sought to determine the molecular mechanism by which IL-4
levels fail to increase during PE.
Several recent studies indicate that miRs may modulate TLR-
mediated immune responses including production and release of
cytokines and chemokines [17–19], expression of adhesion and co-
stimulatory molecules [17,20], and feedback regulation of immune
responses [17,18,21]. miRs are endogenous, small (19–23 nucle-
otides long) single-stranded noncoding RNA that suppress gene
expression either via translational inhibition or mRNA degrada-
tion (or both) and have emerged as key post-transcriptional
regulators of gene expression [22–26]. Recent studies validated
that miRs are abundant in the placenta [27,28] suggesting a role
for miRs in regulating placental gene expression. Dysregulation of
miRs are associated with the pathogenesis of several diseases
including PE. To date, several microarray-based placental miR
profiles have been reported in PE patients [29,30]. Among them,
miR-210 was found in several studies to be elevated significantly in
PE women [29,31]. Whether or not miR-210 expression also
increases in our TLR3-induced PE mouse model is unknown.
Moreover, expression of miR-210 has been shown to be induced
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during hypoxia by hypoxia inducible factor-1a (HIF-1a) [32–35]
and the nuclear factor-kB (NF-kB) p50 subunit [36]. Whether the
same transcription factors also regulate miR-210 expression during
normoxia remains to be elucidated. Although placental miR-210
expression is increased in PE patients, very few miR-210 targets
and their pathophysiological role in PE have been identified so far.
The targets which have been identified to date include iron sulfur
cluster scaffold homologue (ISCU), Ephrin A3, Homeobox A9
(HOXA9), and more recently hydroxysteroid (17-b) dehydroge-
nase [36–39]. Thus there is a need to identify additional miR-210
targets and disseminate their role in the pathophysiology of PE.
In the present study we hypothesized that TLR3 activation via
poly I:C increases placental miR-210 via activation of HIF-1a and
NF-kBp50 which suppresses the STAT6/IL-4 anti-inflammatory
pathway leading to PE. Here we demonstrate that TLR3
activation induced the expression of miR-210, HIF-1a, and NF-
kBp50 in placentas of wild-type mice as well as human CTBs. We
further demonstrate that STAT6 is a novel target of miR-210
using overexpression and inhibition studies in human CTBs and
that STAT6 in turn modulates IL-4. Additionally, poly I:C-treated
pregnant TLR3 KO mice do not exhibit changes in HIF-1a, NF-
kBp50, miR-210, STAT6, and IL-4 levels and do not develop PE.
Results
TLR3 Induced miR-210 Up-regulation in Pregnant Mice
miR-210 expression is increased in placentas of women with PE.
To determine if miR-210 expression is also induced in placentas
from P-PIC mice compared to P mice at gestational day 18 we
performed qRT-PCR reactions. Compared to control P mice,
miR-210 expression increased significantly in P-PIC placentas (4.9
fold, p,0.05, Fig. 1A) and this was associated with increased
systolic blood pressure (P: 9562 mm Hg vs. P-PIC: 13962 mm
Hg, P,0.05; Fig. 1B). Previous studies have shown that miR-210
is induced during hypoxia and HIF-1a was identified as a
transcription factor that binds to the promoter of miR-210 [32–
34]. HIF-1a levels were also increased significantly in P-PIC
placentas (1.5 fold, p,0.05 vs. P placentas, Fig. 1C) suggesting that
Figure 1. HIF-1a and NF-kB induced miR-210 expression in hypertensive P-PIC mice. A. Total RNA (including small RNAs) was isolated from
placentas of both P and P-PIC mice at gestational day 18. miR-210 expression was subsequently determined by qRT-PCR. qRT–PCR of snoRNA 142 was
used for normalization. Results are expressed as mean+SEM for 3 independent experiments. *P,0.05 by Student’s t-test. B. Systolic blood pressures in
P and P-PIC mice were measured at gestational days 0, 13, and 17 via tail-cuff plethysmography. The results are expressed as mean+SEM with 8 mice
in each group. *P,0.05 vs. P. C and D. Immunoblot analyses using anti-HIF-1a and anti-NF-kB antibodies on cell lysates prepared from placentas of P
and P-PIC mice at gestational day 18. b-actin was used as a loading control. The first lane in both immunoblots indicate the molecular weight marker.
Signals from 3 independent experiments were quantified and expressed as a percentage of P. The results are expressed as mean+SEM for percentage
of P for 3 independent experiments. *P,0.05 vs. P.
doi:10.1371/journal.pone.0067760.g001
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HIF-1a likely binds to the promoter of miR-210 under normoxia.
Moreover, the NF-kBp50 subunit also binds to the promoter of
miR-210 under hypoxia [36]. NF-kBp50 levels in P-PIC placentas
increased 2.7 fold compared to P placentas (p,0.05, Fig. 1D)
suggesting that NF-kBp50 also regulates miR-210 expression.
STAT6 is a Target of miR-210
TargetScan [22] and miRanda [40] algorithms suggested
STAT6 as a target of miR-210 (Fig. 2A). Targetscan predicts
one site (Pct , 0.1) whereas miRanda suggests two putative
binding sites for miR-210 in the 39UTR of STAT6 and the
miRSVR score for binding site 1 is 20.587 and for binding site 2
is 20.0257. Since the 39UTR of STAT6 is a predicted target of
miR-210, we measured protein levels of STAT6. STAT6 levels
were decreased significantly in the placentas of P-PIC mice
compared to P mice (Fig. 2B). IL-4 binding to its own receptor
activates STAT6 which in turn activates T helper (Th)-2 lineage-
specific transcription factor GATA3. GATA3 then binds to the
promoter of Th2 cytokines such as IL-4 to regulate their
expression. Because STAT6 levels were decreased in P-PIC
placentas, we sought to determine if IL-4 levels were negatively
affected. IL-4 mRNA levels decreased significantly in placentas
from P-PIC mice compared to P mice (Fig. 2C).
miR-210 Expression in TLR3 Deficient Pregnant Mice
Treated with Poly I:C
In order to determine if TLR3 activation directly contributes to
miR-210 up-regulation, we treated pregnant TLR3 KO mice with
poly I:C (P-PIC TLR3 KO). Interestingly, these mice did not
develop PE-like symptoms including hypertension, endothelial
dysfunction, and proteinuria (data not shown). Placental HIF-1a
and NF-kBp50 levels did not change between P-PIC TLR3 KO
and P TLR3 KO mice (Fig. 3A and 3B). Consistent with the
finding that neither of the transcriptional activators was increased,
we did not observe any increase in placental miR-210 expression
in P-PIC TLR3 KO mice (Fig. 3C). Similarly, placental STAT6
and IL-4 levels did not change in P-PIC TLR3 KO mice (Fig. 3D
and 3E).
TLR3 Induced miR-210 Up-regulation in Human CTBs
To determine the placental etiology we next treated human
CTBs with poly I:C, which is effective up to 48 hrs [41,42]. HIF-
1a levels increased after 24 and 48 hrs of poly I:C treatment
(Fig. 4A). NF-kBp50 levels increased at 6 hrs and returned to basal
levels at 24 hrs (Fig. 4B). miR-210 expression was increased
significantly at 6, 24, and 48 hrs after poly I:C treatment (Fig. 4C).
These results indicate that the transcription factors may bind to
the promoter at different time points and their interplay regulates
the expression of miR-210. STAT6 and IL-4 levels decreased after
6 hrs of poly I:C treatment (Fig. 4D and Fig. 4E).
Validation of STAT6 as a Target of miR-210 in CTBs
To investigate the activity of miR-210, we transfected CTBs
with Pre-miRTM miRNA precursors that are stable, chemically
modified double-stranded RNAs that mimic mature endogenous
miRs. We confirmed increased expression of miR-210 in CTBs
transfected with a pre-miR mimetic of miR-210 by qRT-PCR
(Fig. 5A). The pre-miR mimetic of miR-210 significantly reduced
STAT6 levels by ,40–50% as determined by immunoblot
compared to the control, a random precursor (Fig. 5B). IL-4
expression also significantly decreased ,40–50% compared to
control (Fig. 5C). To further investigate the role of miR-210 on
STAT6/IL-4 expression, anti-miR-210 was transfected into
human CTBs. Inhibition of miR-210 was similar at either 100
or 200 nM thus we used 100 nM for all subsequent studies
(Fig. 6A). After 48 hrs of transfection, a significant increase in
STAT6 (Fig. 6B) and IL-4 (Fig. 6C) expression was observed after
miR-210 inhibition. These results indicate a direct role of
endogenous miR-210 in the negative regulation of STAT6 and
IL-4.
Discussion
PE is a multifactorial disease and the role miRs play in the
pathophysiology of PE is only beginning to emerge. Here we
demonstrate that TLR3 activation induces miR-210 expression via
the transcription factors HIF-1a and NF-kBp50 and that STAT6
is a target of miR-210. The induction of miR-210 by TLR3
decreases STAT6 and IL-4 which may contribute to the
inflammatory state evident in PE.
Pineles et al. published a study on the differential expression of
miRs where 157 miRs were screened in both PE and normal
placentas [29]. miR-210 was increased significantly in PE
placentas and mostly localized in the syncytiotrophoblasts. Target
genes of miR-210 were predicted to regulate immune responses,
apoptosis, and lipid metabolism. Zhu et al. performed placental
miR microarray analyses from both mild and severe PE patients.
Thirty-four miRs were expressed differentially in PE placentas
compared to normal placentas [31]. Of these, 11 miRs were
overexpressed and miR-210 expression was increased 3.6-fold in
severe PE patients. A study by Enquobahrie et al. indicated a
significant 1.5-fold increase in miR-210 expression in PE placentas
[43]. Our results demonstrate for the first time that TLR3
activation in human CTBs significantly increases miR-210
expression and in our TLR3-induced mouse model of PE
Figure 2. Placental STAT6 and IL-4 levels are decreased
significantly in P-PIC mice. A. Schematic of human STAT6 39-UTR
sequence targeted by miR-210. The predicted seed regions by both
TargetScan and miRanda algorithms are indicated. B. Placental cell
lysates from both P and P-PIC mice at gestational day 18 were
subjected to immunoblot analyses using anti-STAT6 antibodies.
Immunoblot analysis with an anti-b-actin antibody served as a loading
control. The first lane in the immunoblot indicates the molecular weight
marker. C. mRNA levels of IL-4 were determined by qRT–PCR after
isolation of total RNA from placentas of both P and P-PIC mice at
gestational day 18. qRT–PCR of GAPDH was used for normalization.
Results are expressed as mean+SEM for 3 independent experiments.
*P,0.05 vs. P.
doi:10.1371/journal.pone.0067760.g002
MiR-210 Regulates STAT6 Levels
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e67760
placental miR-210 expression is increased significantly. Further-
more, P-PIC TLR3 KO mice, which exhibited no symptoms of
PE, did not exhibit an increase in placental miR-210 expression
compared to P TLR3 KO mice. Recent studies indicate that miR-
210 is also up-regulated in the plasma of PE women [44]. Thus,
increased miR-210 expression may serve as a potential biomarker
for PE. Currently, only protein markers in plasma or serum are
used for predicting PE [45], however one limitation is that none of
the current detection methods are reliable predictors of PE. Levels
of miR-210 may be a more accurate predictor of PE as miR-210
expression in serum samples increases with the severity of PE [44],
but this remains to be determined.
The promoter of miR-210 has several putative transcription
factor binding sites [34]. It has been previously shown that HIF-1a
regulates the expression of miR-210 in a variety of tumor types
through a hypoxia-responsive element [34]. In support, several
studies showed that the expression of miR-210 increases upon
exposure to hypoxia, which implies that miR-210 may be a
potential marker of hypoxia. PE pregnancies are associated with
poor placentation that can cause focal regions of ischemia/
hypoxia in the placenta which in turn may cause increased miR-
210 expression. In addition to hypoxia, HIF-1a expression is also
induced under normoxic conditions as HIF-1a levels were up-
regulated in the prostate cancer cell line PC3 but not LNCaP [46].
Our results demonstrate that HIF-1a levels were also increased in
the placentas of P-PIC mice as well as normoxic CTBs treated
with poly I:C in a time-dependent manner. HIF-1a induced under
normoxic conditions may in turn bind to the miR-210 promoter
Figure 3. No significant change in placental HIF-1a, NF-kB, miR-210, STAT6, and IL-4 levels in TLR3 KO P-PIC mice. A and B. Placental
cell lysates from both P TLR3 KO and P-PIC TLR3 KO mice at gestational day 18 were subjected to immunoblot analyses using anti-HIF-1a and anti-NF-
kB antibodies. No significant difference was noted in HIF-1a and NF-kB levels between P TLR3 KO and P-PIC TLR3 KO mice. The first lane in the
immunoblot A indicates the molecular weight marker. C. Placental miR-210 levels in both P TLR3 KO and P-PIC TLR3 KO mice were determined by
qRT-PCR. D. No difference was noted in placental STAT6 levels between P TLR3 KO and P-PIC TLR3 KO mice by immunoblot analysis. The first lane
indicates the molecular weight marker. Because we did not observe any significant difference in STAT6 levels between WT P and TLR3 KO P mice
indicating that deficiency of TLR3 in mice did not alter baseline STAT6 levels we did not include this data in Fig. 3. E. IL-4 mRNA levels were
determined by qRT–PCR from placentas of both P TLR3 KO and P-PIC TLR3 KO at gestational day 18. GAPDH was used for normalization. Results are
expressed as mean+SEM for 3 independent experiments. *P,0.05 vs. P TLR3 KO.
doi:10.1371/journal.pone.0067760.g003
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and up-regulate its expression. Apart from the CTBs, whether or
not HIF-1a up-regulation occurs in other cell types in the placenta
following TLR3 activation remains to be determined. Recently,
another transcription factor, the NF-kBp50 subunit, was also
shown to bind the miR-210 promoter and regulate its expression
[36]. We demonstrate that CTBs treated with poly I:C as well as
placentas from P-PIC mice have elevated levels of NF-kBp50
whereas P-PIC TLR3 KO placentas exhibit no change in
expression of NF-kBp50 or HIF-1a. NF-kB levels were also
increased in placentas of PE women compared to normotensive
women as detected by immunohistochemistry [47]. Taken
together our data suggests that both of these transcription factors
are up-regulated following TLR3 activation and that their
interplay contributes to miR-210 transcriptional up-regulation.
Several targets of miR-210 have been identified through a
combination of target prediction algorithms and biochemical
assays. So far, hydroxysteroid (17-b) dehydrogenase 1, ISCU,
Ephrin A3, and HOXA9 have been identified in PE [36,38,39].
The role of miR-210 in angiogenesis and iron metabolism are
well established but the role of miR-210 in the regulation of genes
related to immune responses are unknown. Pineles et al. used
miRBase to determine putative mRNA targets of miR-210 and
miR-210 targets are enriched in genes related to immune
responses [29]. Of the several immune related targets, we
demonstrate using overexpression and inhibition studies that
STAT6 is a bona-fide target of miR-210.
IL-4 binds IL-4 Receptor a (IL-4Ra) and activates STAT6
leading to increased expression of the GATA3. GATA3 binds to
target regulatory sequences of Th2 cytokine genes including IL-4
thus promoting expression [48]. We have shown that IL-4 levels
fail to increase in the serum of P-PIC mice which exhibit
inflammation and PE-like symptoms [13]. These results taken
Figure 4. Poly I:C increased HIF-1a and NF-kB which induced miR-210 leading to decreased STAT6 and IL-4 in human CTBs. A and B.
CTB cells were treated with poly I:C (2 ug/ml) for 6, 24, or 48 hrs. Cell lysates were isolated and immunoblotting was performed using anti-HIF-1a and
anti-NF-kB antibodies. Results are expressed as mean+SEM for 3 independent experiments. The first lane in the immunoblots in A and B indicate the
molecular weight marker. C. Under the same conditions as above, miR-210 expression increased following TLR3 activation with the peak induction
seen at 48 hrs as determined by qRT-PCR. D. Poly I:C treatment for 48 hrs showed the strongest down-regulation of STAT6 as determined by
immunoblotting. The first and last lanes in the immunoblot indicate the molecular weight marker. E. Relative fold-change in IL-4 levels following poly
I:C treatment in CTB cells. Results are expressed as mean+SEM and *P,0.05 vs. P.
doi:10.1371/journal.pone.0067760.g004
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together suggest that IL-4 plays an important role in maintaining
immune system homeostasis during pregnancy. In this paper we
demonstrate that IL-4 expression in placentas of P-PIC mice and
in CTBs decreased significantly following TLR3 activation.
Moreover, overexpression of miR-210 in CTBs decreased IL-4
expression and vice-versa suggesting that decreased levels of
STAT6 contribute to the decrease in IL-4 expression.
In summary, our work suggests that miR-210 expression is
increased by TLR3 possibly via HIF-1a and NF-kB leading to
decreased levels of STAT6 and IL-4 and may partly contribute to
the development of PE. Several recent papers demonstrate the
efficacy of administration of antimiR oligos. Among them, a miR-
208a antimiR has been shown to suppress fibrosis by reducing
myosin 7 expression and improve survival in Dahl salt-sensitive
rats [49]. miR-21 inhibitors were effective in suppressing
extracellular matrix production in several diseases such as
muscular dystrophy, renal fibrosis, and pulmonary fibrosis [50–
52]. Furthermore, miR-122 antimiR oligos have been successfully
used for the treatment of HCV in recent Phase I and Phase II
clinical trials. Therefore, miRs inhibitors may be a promising
therapeutic for a variety of diseases. Based on our results, miR-210
inhibition may ameliorate the symptoms of PE.
Materials and Methods
Animals/Treatments
Male breeder mice, female mice (C57BL/6J) stock #002253,
and TLR3+/2 mice (B6;129S1-Tlr3tm1Flv/J) stock #005217 were
Figure 5. miR-210 mimic decreased STAT6 and IL-4 levels in human CTBs. CTBs were transfected with either scramble (negative control) or
different concentrations of miR-210 mimic (30 nM or 100 nM). A. After 48 hrs of treatment, RNA was isolated and qRT-PCR was performed to
determine miR-210 levels. U6 RNA was used as the normalization control. Results are expressed as mean+SEM for 3 independent experiments. B. Cell
extracts were prepared and protein levels of STAT6 were determined by immunoblot. Overexpression of miR-210 decreased STAT6 levels compared
to scramble (negative control). The first lane in the immunoblot indicates the molecular weight marker. C. Total RNA was isolated and IL-4 levels were
determined by qRT-PCR. Relative expression of IL-4 was determined. Results are expressed as mean+SEM and *P,0.05 vs. scramble.
doi:10.1371/journal.pone.0067760.g005
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obtained from The Jackson Laboratory. TLR3+/2 mice were
intercrossed to generate TLR32/2 mice and used for the studies
reported here. All mice were acclimated in our facility and housed
in a temperature-controlled room (23uC) with a 12-h:12-h light-
dark cycle. Adult male and female mice (8–12 weeks old) were
mated and female WT or TLR3 KO mice were grouped either as
pregnant (P) or pregnant treated with poly I:C (P-PIC). Only P-
PIC mice in both WT and TLR3 KO groups received i.p.
injections of poly I:C (20 mg/kg) on gestational days 13, 15 and 17
as described previously [13,14]. P mice in both WT and TLR3
KO groups received injections of saline (vehicle) on corresponding
days. Both WT and TLR3 KO pregnant female mice treated with
saline/poly I:C were euthanized on gestational day 18 and organs
were harvested, snap frozen, and stored at 280uC for subsequent
studies. All animals were maintained in the Scott & White
Healthcare Animal Facility under specific pathogen-free condi-
tions. All experimental procedures were approved by the Texas
A&M Health Science Center/Scott & White Healthcare Institu-
tional Animal Care and Use Committee in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.
Blood Pressure Measurements
Systolic arterial blood pressure was measured in conscious
animals using non-invasive, computerized tail-cuff plethysmogra-
Figure 6. Anti-miR-210 increased STAT6 and IL-4 levels in human CTBs. CTB cells were transfected with either scramble (negative control) or
different concentrations of a miR-210 inhibitor (100 nM or 200 nM). A. After 48 hrs of treatment, RNA was isolated and qRT-PCR was performed to
determine miR-210 levels. U6 RNA was used as the normalization control. Results are expressed as mean+SEM for 3 independent experiments. B. Cell
extracts were prepared and protein levels of STAT6 were determined by immunoblotting. Down-regulation of miR-210 increased STAT6 levels
compared to scramble (negative control). The first lane in the immunoblot indicates the molecular weight marker. C. Total RNA was isolated and IL-4
levels were determined by qRT-PCR. Relative expression of IL-4 was determined. Results are expressed as mean+SEM and *P,0.05 vs. scramble.
doi:10.1371/journal.pone.0067760.g006
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phy (IITC, Inc.) as described previously [53]. Mice were
acclimatized for 3 days by placing them in the restrainer prior
to data collection. Measurements were taken at baseline and on
gestational days 13 and 17 prior to injections on that day. The
average of 3 measurements was used for data analysis.
Cell Culture Studies
The human extravillous CTB cell line, SGHPL-4, was derived
from first trimester chronic villous tissue and provided by Dr. Guy
Whitley (St. George’s Hospital Medical School, London, UK)
[54]. SGHPL-4 cells were cultured in Ham’s F-10 media
supplemented with 10% fetal bovine serum, penicillin G,
streptomycin, and l-glutamine (Sigma). Cells were grown at
37uC in 5% CO2.
Immunoblots
Cell lysates were prepared from mouse placental tissues and
human CTBs using a cell lysis buffer (Cell Signaling) with protease
inhibitors and subjected to electrophoresis with SDS–PAGE (4–
12%) gels. The blots were transferred onto nitrocellulose
membranes (Millipore) and Western blot analyses were performed
using the following primary antibodies: STAT6 1:1,000 (Cell
Signaling), HIF-1a 1:500 (Novus Biologicals for mouse), HIF-1a
(R&D Systems for human), and NF-kB 1:1000 (Cell Signaling).
Beta-actin 1:10,000 (Sigma) was used as a loading control. The
secondary antibodies consisted of anti-rabbit and anti-mouse IgGs
conjugated to Alexa-Fluor 680 or IRDye 800 (LI-COR Biosci-
ences). Infrared visualization was used followed by densitometric
analyses using the provided software (Odyssey System, LI-COR
Biosciences).
qRT-PCR
Total RNA (including miRs) from placentas and CTBs was
extracted using an miRNeasy isolation kit (Qiagen) and quality
and quantity was determined using a NanoDrop spectrophotom-
eter. miRs were further isolated from total RNA using an RT2
qPCR-grade miRNA isolation kit (SABiosciences). cDNA was
prepared using a RT2 miRNA First Strand kit (SABiosciences) and
miRNA expression was assessed by real-time PCR using SYBR
Green (SABiosciences). The expression of miR-210 was normal-
ized to mouse snoRNA 142 for mouse placentas and to human U6
for CTBs. All the above-mentioned primers were obtained from
SABiosciences. To determine IL-4 mRNA levels, first-strand
cDNAs were synthesized with reverse transcriptase (Qiagen) using
total RNA (1 mg) extracted with an RNeasy kit (Qiagen) and
amplified using a SYBR Green PCR master mix (SABiosciences)
per the manufacturer’s protocol. Primers used for human IL-4 and
GAPDH were purchased from SABiosciences. The forward and
reverse primers for the mouse IL-4 gene that were used are-
Forward primer: 59 GGT CAC AGG AGA AGG GAC GCC 39
Reverse primer: 59 TGC GAA GCA CCT TGG AAG CCC 39
and the GAPDH mouse primers are- Forward primer- 59 TCA
CCA CCA TGG AGA AGG C 39 Reverse primer- 59 GCT AAG
CAG TTG GTG GTG CA 39. Reactions were carried out in a
96-well optical reaction plate using a Real-Time PCR Detection
System (Stratagene, Mx3000p). Reactions proceeded with an
initial 10 min incubation at 95uC followed by 40 cycles of
amplification: 95uC for 15 sec and 60uC for 1 min. Dissociation
curves for each primer were verified to have single peaks.
Comparative quantitation was performed by comparing the Ct
value obtained and relative miRNA/mRNA abundance was
calculated using the 2DDCt method [55].
miR-210 Overexpression and Inhibition
Transfection of miR-210 mimics (pre-miRs; Dharmacon) or
miR-210 inhibitors (anti-miRs; Ambion) was performed in human
CTBs using the reverse transfection technique recommended for
use with the siPORT NeoFX transfection reagent (Life Technol-
ogies). Control scramble sequence was used for each transfection
reaction. Transfections were carried out when cells were 70%
confluent according to the manufacturer’s protocol using 3 mL of
transfection reagent and a final concentration of 30, 100, or
200 nM of each oligonucleotide per well in a 6-well plate. Media
was replaced after 16 hrs and experiments were performed 24 hrs
later.
Statistical Analyses
Data are presented as mean 6 SEM. SigmaStat 12 (Systat
Software) was used to perform all statistical analyses. Student’s t-
test was used for analyses within human CTBs and an ANOVA
was used for comparisons between groups of mice for all measures
followed by the Student-Newman-Keuls post hoc test. The
significance level was 0.05.
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